US2016361413A1PendingUtilityA1

Compounds for use in the treatment of alzheimer's disease

46
Assignee: UNIV JOHANNESBURG WITWATERSRANDPriority: Sep 19, 2011Filed: May 10, 2016Published: Dec 15, 2016
Est. expirySep 19, 2031(~5.2 yrs left)· nominal 20-yr term from priority
Inventors:Stefan Franz Thomas WeissKatarina JovanovicDanielle GonsavlesBianca Da Costa DiasStefan KnackmussUwe ReuschMelvyn LittleMarc Weinberg
A61K 2039/505A61K 31/7105C07K 2317/76C07K 16/26A61K 39/3955C12N 15/1138C07K 16/28
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (β) and gamma (γ) secretases and amyloid beta peptide (Aβ), and also relates to a method of reducing Aβ shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD.

Claims

exact text as granted — not AI-modified
1 - 62 . (canceled) 
     
     
         63 . A method for reducing the concentration of amyloid beta peptide (Aβ) in a human or animal suffering from Alzheimer's Disease (AD), the method comprising: contacting a cell surface protein with a cell surface protein specific antibody, or any fragment thereof, such that binding occurs between a surface epitope of the cell surface protein and the cell surface protein specific antibody therein hindering the proteolytic cleavage of APP by beta (β) and gamma (γ) secretases, which in turn causes a decrease in the concentration of amyloid beta peptide (Aβ). 
     
     
         64 . The method according to  claim 63 , wherein the cell surface protein is a laminin receptor protein. 
     
     
         65 . The method according to  claim 64 , wherein the laminin receptor protein is 37 kDa/67 kDa laminin receptor (LRP/LR) or a protein having at least 80% or greater homology to LRP/LR. 
     
     
         66 . The method according to  claim 63 , wherein the antibody or fragment thereof is raised against the cell surface protein. 
     
     
         67 . The method according to  claim 63 , wherein the antibody or fragment thereof is an anti-laminin receptor specific antibody or fragment thereof. 
     
     
         68 . The method according to  claim 67 , wherein the anti-laminin receptor specific antibody or fragment thereof is an anti-LRP/LR specific antibody or fragment thereof or an antibody or fragment thereof having at least 80% or greater homology to anti-LRP/LR specific antibody or fragment thereof. 
     
     
         69 . The method according to  claim 68 , wherein the anti-LRP/LR specific antibody or fragment thereof is IgG1-iS18 or a fragment thereof. 
     
     
         70 . The method according to  claim 63 , wherein the cell surface protein is 37 kDa/67 kDa laminin receptor (LRP/LR) and the cell surface protein specific antibody is IgG1-iS18 or a fragment thereof.

Join the waitlist — get patent alerts

Track US2016361413A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.